Katarina Luptakova - Sep 5, 2023 Form 4 Insider Report for Xilio Therapeutics, Inc. (XLO)

Role
Chief Medical Officer
Signature
/s/ Julia Walcott, Attorney-in-Fact
Stock symbol
XLO
Transactions as of
Sep 5, 2023
Transactions value $
$0
Form type
4
Date filed
9/7/2023, 04:26 PM
Next filing
Jan 3, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XLO Stock Option (Right to Buy) Award $0 +106K $0.00 106K Sep 5, 2023 Common Stock 106K $2.79 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on September 5, 2023 and will vest in equal monthly installments beginning on October 1, 2023 through September 1, 2027.